Advancing early cancer screening and detection.
Anpac Bio’s Cancer Differentiation Analysis can detect multiple cancers with high sensitivity and specificity.
Anpac Bio uses proprietary algorithms to measure and analyze these signals at multiple biological levels.
Detects the risks of 26 different types of cancer—often identifying cancer at its early stages: Covering 80% of cancer incidences in China from 2013 to 2018
128 issued patents granted to date around its Cancer Differentiation Analysis (“CDA”) technology.
Significant cost advantages compared to other screening technologies
Read the research Anpac Bio scientists presented at the American Society of Clinical Oncology, the San Antonio Breast Cancer Symposium, and the Nobel Prize Laureate Summit on Biomedical Sciences.
We work with clinicians and scientists to improve our understanding of the biophysics of cancer across the world in the emerging liquid biopsy field.
Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.Read the full article